Dr. Kamdar has served as a member of the Evofem Biosciences board of directors since January 2018 and is currently the Chair of the Nominating Committee. Dr. Kamdar is a Managing Partner of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005. Dr. Kamdar is current Chair of the board of directors and CEO of Aspen Neuroscience and chair of the board of directors of Truvian Sciences. She also serves on the board of directors of Epic Sciences, Obalon Therapeutics, Omniome, ROX Medical, Sera Prognostics and Singular Genomics. Past investments include Ariosa (acquired by Roche), Corthera (acquired by Novartis), BiPar Sciences (acquire by Sanofi-Aventis) and Achaogen.
Formerly, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Prior to joining MPM, Dr. Kamdar was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Dr. Kamdar is the author of ten papers as well as the inventor on seven patents. Dr. Kamdar received her B.A. from Northwestern University and Ph.D. in biochemistry and genetics from Emory University.
Dr. Kamdar serves as an advisory board member of Dr. Eric Topol's NIH supported Clinical and Translational Science Award for Scripps Medicine and is also on the non-profit board for Access Youth Academy, an organization that is transforming the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash.
What is Kim P. Kamdar's net worth?
The estimated net worth of Kim P. Kamdar is at least $1,942.34 as of August 14th, 2023. Ms. Kamdar owns 132,132 shares of Evofem Biosciences stock worth more than $1,942 as of November 5th. This net worth evaluation does not reflect any other assets that Ms. Kamdar may own. Learn More about Kim P. Kamdar's net worth.
How do I contact Kim P. Kamdar?
Has Kim P. Kamdar been buying or selling shares of Evofem Biosciences?
Kim P. Kamdar has not been actively trading shares of Evofem Biosciences during the past quarter. Most recently, on Friday, June 18th, Kim P. Kamdar bought 80 shares of Evofem Biosciences stock. The stock was acquired at an average cost of $146.25 per share, with a total value of $11,700.00. Following the completion of the transaction, the director now directly owns 154 shares of the company's stock, valued at $22,522.50. Learn More on Kim P. Kamdar's trading history.
Who are Evofem Biosciences' active insiders?
